09122018_Tarveda_Brian-Headshot-blue.jpg

BRIAN ROBERTS

CHIEF FINANCIAL OFFICER

Brian Roberts joined Tarveda Therapeutics as Chief Financial Officer in January 2018. Brian has nearly 25 years of finance, capital markets and operations experience spanning the lifesciences, medtech and media industries with a proven track record of delivering positive results and driving shareholder value. Mr. Roberts served as Chief Financial and Operating Officer at Avedro, Inc., a privately held biotechnology company leading the organization through FDA approval, manufacturing readiness and commercial launch of its lead combination drug and medical device product. Previously, he served as Chief Financial Officer at Insulet Corporation, (NASDAQ: PODD) a leader in tubeless insulin pump technology. During his tenure, Insulet grew rapidly to nearly $300 million in revenue with a valuation of over $2 billion. Prior to Insulet, Brian served as CFO for Jingle Networks, acquired by Marchex, Inc., and as CFO for Digitas, (NASDAQ: DTAS) a leading digital marketing and media services firm acquired for $1.3 billion by Publicis Groupe. Brian has also held finance positions at Idiom Technologies, Inc., the Monitor Group and as an auditor with Ernst & Young LLP. Brian currently serves as Director and Audit Chairman for ViewRay, Inc., (NASDAQ:VRAY), a leader in MRI-guided radiation therapy, and as Director and Audit Chairman for Valeritas Holdings, Inc. (NASDAQ:VLRX), the maker of V-Go®, a daily insulin delivery device for people living with diabetes. Mr. Roberts holds a Bachelor of Science in Accounting and Finance from Boston College and is a Certified Public Accountant.